French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
US-based Acorda Therapeutics has sued Actavis for infringing four patents covering its multiple sclerosis (MS) drug Ampyra (dalfampridine).
Tennessee-based law firm Stites & Harbison PLLC has expanded its IP and technology practice with the hire of life sciences partners Kelly Hollowell and Justin McNaughton.
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.
An ex-employee for a large Chinese seed production company has been arrested in the US for conspiring to steal trade secrets from US agricultural companies including Monsanto.
Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.
Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.
Actavis’s newly-acquired subsidiary Forest Laboratories has bought drug development company Furiex Pharmaceuticals for $1.1 billion.
The head of IP at a major pharmaceutical company is set to be named as the next director of the US Patent and Trademark Office, reports have claimed.
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion.